Calmer Therapy Bed for Premature Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests the Calmer therapy bed to determine if it aids premature infants' growth and development in the NICU. Calmer mimics skin-to-skin contact by providing a soothing surface, heartbeat sounds, and breathing motions tailored to each baby using their parents' recordings. The trial will compare the growth and brain activity of babies using Calmer for a few hours daily over 2-3 weeks with those receiving regular NICU care. Eligible participants are preterm infants born at 26-30 weeks who are on breathing support and have at least one English-speaking parent for consent. As an unphased trial, this study offers a unique opportunity to contribute to innovative research that could improve care for premature infants.
Will I have to stop taking my current medications?
The trial information does not specify whether participants must stop taking their current medications. It focuses on preterm infants in the NICU and does not mention any medication changes.
What prior data suggests that the Calmer therapy bed is safe for preterm infants?
Research has shown that the Calmer therapy bed is safe for premature babies. In a study with 58 preterm infants, Calmer reduced stress and maintained steady brain blood flow, similar to the usual care method known as facilitated tucking. Babies safely used Calmer for up to 6 hours a day.
Another study found that babies using Calmer maintained normal oxygen levels in their brains, comparable to those who received human touch. This indicates that Calmer does not harm critical functions like brain oxygen levels.
These findings suggest that Calmer is well-tolerated and does not harm babies. Both parents and hospital staff felt comfortable using Calmer, which supports its safety in hospitals.12345Why are researchers excited about this trial?
The Calmer therapy bed for premature infants is unique because it offers a gentle, non-invasive way to support the development of preemies in a neonatal intensive care unit (NICU) setting. Unlike traditional incubator care, which primarily focuses on maintaining a stable environment, Calmer provides targeted therapy directly within the incubator for at least 3 hours a day. Researchers are excited about this approach because it could enhance the sensory environment for premature infants, potentially promoting better growth and neurological development during those critical early weeks.
What evidence suggests that the Calmer therapy bed is effective for reducing stress in preterm infants?
In this trial, some participants will receive the Calmer therapy, which previous studies have shown to reduce stress in premature babies during routine procedures. It stabilized their heart rates and ensured normal blood flow to the brain, similar to the benefits of human touch. Calmer mimics skin-to-skin care by providing a gentle heartbeat sound and breathing motion customized for each baby. Premature babies using Calmer maintained normal oxygen levels in their brains, crucial for healthy brain development. While more research is needed to understand the long-term effects, early findings suggest that Calmer could support growth and brain development in premature babies.12345
Who Is on the Research Team?
Liisa Holsti, PhD
Principal Investigator
The University of British Columbia
Manon Ranger, PhD
Principal Investigator
The University of British Columbia
Are You a Good Fit for This Trial?
This trial is for preterm infants in the NICU at BC Women's Hospital, born between 26-30 weeks gestational age. They can be on airway support but must not have major health issues like congenital anomalies, infections at enrolment, neurological injuries, cardiovascular instability or a history of maternal substance abuse.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Infants receive either Calmer therapy or standard NICU care for 2-3 weeks
Follow-up
Participants are monitored for growth and brain development outcomes after treatment
Extension
Potential continuation of monitoring for long-term outcomes in a larger RCT
What Are the Treatments Tested in This Trial?
Interventions
- Calmer
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of British Columbia
Lead Sponsor
Women's Health Research Institute of British Columbia
Collaborator